Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.08 billion
P/E Ratio 55.56
Dividend Yield 0.00%
Shares Outstanding 726.10 million
Earnings per share -1.646
Dividend per share 0.12
Year To Date Return -8.26%
Earnings Yield 1.80%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Healius Ltd (ASX: HLS)
    Latest News

    A diverse group of people form a circle at a park and raise their arms together.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was a disappointing end to the trading week today for ASX investors.

    Read more »

    A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy NAB shares
    Share Fallers

    Is it time to buy FY24's worst-performing ASX shares?

    Are there bargains to be found amongst the ASX's worst shares of FY24?

    Read more »

    A red house cut out leaning on a piggy bank.
    Share Market News

    How ASX shares vs. property performed in June

    We reveal the property price growth for each city and regional market and the top 5 gainers of the ASX…

    Read more »

    A man slumps crankily over his morning coffee as it pours with rain outside.
    Share Fallers

    These were the five worst ASX 200 shares to own in FY24

    The last financial year was not kind to these stocks.

    Read more »

    A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
    Share Gainers

    These were the best performing ASX 200 shares in June

    These shares smashed the market in June. But why?

    Read more »

    A woman stares at the candle on her cake, her birthday has fizzled.
    Share Market News

    Here are the top 10 ASX 200 shares today

    The markets ended the trading week on a sad note today.

    Read more »

    The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    It was another horrid day for ASX investors this hump day.

    Read more »

    A woman in an office is being pressured, she rubs her temples from the stress.
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see which shares short sellers are targeting this week.

    Read more »

    A person sitting at a desk smiling and looking at a computer.
    Share Gainers

    3 ASX 200 stocks leading the charge higher in June

    These three ASX 200 stocks have smashed the benchmark returns in the first week of June. But how?

    Read more »

    Concept image of man holding flames in both hands.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    The ASX 200 had a strong start to the trading week this Monday.

    Read more »

    most shorted ASX shares
    Share Market News

    These are the 10 most shorted ASX shares

    Let's see which shares short sellers are targeting this week.

    Read more »

    A woman stares at the candle on her cake, her birthday has fizzled.
    Share Market News

    Here are the top 10 ASX 200 shares today

    ASX investors endured another negative day this Thursday.

    Read more »

    Frequently Asked Questions

    Yes, Healius has historically paid two fully franked shareholder dividends a year.

    Healius has generally paid its shareholder dividends in March/April and September/October.

    Healius Ltd listed on the ASX on 3 July 1998.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    07 Sep 2022 $0.0600 100.00% Final 21 Sep 2022
    24 Mar 2022 $0.1000 100.00% Interim 05 Apr 2022
    13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
    25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
    26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
    29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
    15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019
    27 Aug 2018 $0.0550 100.00% Final 17 Sep 2018
    16 Mar 2018 $0.0510 100.00% Interim 27 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 18 Sep 2017
    17 Mar 2017 $0.0480 100.00% Interim 28 Mar 2017
    01 Sep 2016 $0.0640 100.00% Final 19 Sep 2016
    18 Mar 2016 $0.0560 50.00% Interim 29 Mar 2016
    26 Aug 2015 $0.1100 50.00% Final 14 Sep 2015
    18 Mar 2015 $0.0900 100.00% Interim 07 Apr 2015
    27 Aug 2014 $0.1100 100.00% Final 15 Sep 2014
    17 Mar 2014 $0.0900 100.00% Interim 07 Apr 2014
    16 Sep 2013 $0.1100 100.00% Final 08 Oct 2013
    18 Mar 2013 $0.0650 100.00% Interim 08 Apr 2013
    17 Sep 2012 $0.0600 100.00% Final 08 Oct 2012
    26 Mar 2012 $0.0500 100.00% Interim 16 Apr 2012
    19 Sep 2011 $0.0500 100.00% Final 10 Oct 2011
    21 Mar 2011 $0.0300 100.00% Interim 11 Apr 2011
    20 Sep 2010 $0.1000 100.00% Final 11 Oct 2010
    05 Mar 2010 $0.1500 100.00% Interim 29 Mar 2010
    07 Sep 2009 $0.0700 100.00% Final 28 Sep 2009
    16 Feb 2009 $0.0700 100.00% Interim 09 Mar 2009
    08 Sep 2008 $0.0500 100.00% Final 09 Oct 2008
    22 Feb 2008 $0.2200 100.00% Interim 17 Mar 2008
    31 Aug 2007 $0.2400 100.00% Final 24 Sep 2007
    09 Mar 2007 $0.2100 100.00% Interim 02 Apr 2007
    09 Oct 2006 $0.0800 100.00% Special Cash 30 Oct 2006
    04 Sep 2006 $0.2200 100.00% Final 25 Sep 2006
    20 Feb 2006 $0.2000 100.00% Interim 13 Mar 2006
    22 Aug 2005 $0.1300 100.00% Final 12 Sep 2005
    08 Apr 2004 $0.0750 100.00% Interim 03 May 2004

    HLS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Healius Ltd

    Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.

    The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres. 

    The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics. 

    HLS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    18 Jul 2024 $1.49 $-0.01 -0.67% 1,637,826 $1.50 $1.51 $1.47
    17 Jul 2024 $1.50 $0.03 2.04% 1,704,575 $1.52 $1.54 $1.50
    16 Jul 2024 $1.47 $0.00 0.00% 1,587,996 $1.47 $1.48 $1.45
    15 Jul 2024 $1.47 $0.00 0.00% 908,703 $1.49 $1.50 $1.46
    12 Jul 2024 $1.47 $0.02 1.38% 1,208,036 $1.47 $1.48 $1.46
    11 Jul 2024 $1.45 $0.00 0.00% 1,117,968 $1.47 $1.48 $1.43
    10 Jul 2024 $1.45 $0.02 1.40% 1,615,904 $1.42 $1.46 $1.39
    09 Jul 2024 $1.43 $-0.01 -0.69% 1,203,489 $1.45 $1.45 $1.42
    08 Jul 2024 $1.44 $-0.03 -2.05% 1,129,326 $1.47 $1.48 $1.44
    05 Jul 2024 $1.47 $0.05 3.52% 1,291,126 $1.42 $1.48 $1.41
    04 Jul 2024 $1.42 $-0.01 -0.70% 2,091,530 $1.45 $1.45 $1.40
    03 Jul 2024 $1.43 $0.00 0.00% 1,586,014 $1.43 $1.46 $1.42
    02 Jul 2024 $1.43 $-0.01 -0.70% 1,905,438 $1.43 $1.44 $1.39
    01 Jul 2024 $1.44 $-0.07 -4.67% 1,249,534 $1.50 $1.50 $1.42
    28 Jun 2024 $1.50 $0.02 1.36% 3,536,603 $1.48 $1.53 $1.45
    27 Jun 2024 $1.48 $0.00 0.00% 4,231,740 $1.48 $1.50 $1.46
    26 Jun 2024 $1.48 $-0.02 -1.33% 5,236,494 $1.40 $1.51 $1.39
    25 Jun 2024 $1.50 $0.00 0.00% 5,582,880 $1.47 $1.52 $1.41
    24 Jun 2024 $1.50 $-0.03 -1.97% 1,732,100 $1.54 $1.55 $1.47
    21 Jun 2024 $1.53 $0.01 0.66% 3,882,559 $1.55 $1.55 $1.49
    20 Jun 2024 $1.52 $0.02 1.34% 4,591,902 $1.49 $1.53 $1.46
    19 Jun 2024 $1.49 $0.02 1.37% 2,446,854 $1.46 $1.51 $1.43

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 May 2024 Kathryn (Kate) McKenzie Transfer 2,559 $3,224
    Off-market transfer.
    21 May 2024 Kathryn (Kate) McKenzie Transfer 2,559 $3,224
    Off-market transfer.
    14 May 2024 Gordon Davis Transfer 40,214 $53,886
    As advised by the company. Transfer of NED Restricted shares to the custodian
    under the Healius NED Share Plan.
    14 May 2024 Gordon Davis Transfer 40,214 $53,886
    As advised by the company. Transfer of NED Restricted shares to the custodian
    under the Healius NED Share Plan.
    14 May 2024 John Mattick Transfer 15,093 $20,224
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan
    14 May 2024 Sally Evans Transfer 51,332 $68,784
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Sally Evans Transfer 51,332 $68,784
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Charlie Taylor Transfer 16,450 $22,043
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Charlie Taylor Transfer 16,450 $22,043
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    15 Mar 2024 Charlie Taylor Buy 16,450 $25,000
    Conversion of securities.
    15 Mar 2024 Charlie Taylor Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    15 Mar 2024 Sally Evans Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    15 Mar 2024 Sally Evans Buy 16,450 $25,000
    Conversion of securities. vwap
    28 Feb 2024 Maxine Jaquet Issued 512,645 $1,499,999
    Issue of securities. vwap, 884,504 Performance Rights
    30 Jan 2024 Maxine Jaquet Expiry 1,667,805 $2,334,927
    Options expired.
    21 Dec 2023 Charlie Taylor Buy 50,000 $74,500
    On-market trade.
    19 Dec 2023 Charlie Taylor Buy 50,000 $74,815
    On-market trade.
    14 Dec 2023 Maxine Jaquet Issued 112,078 $134,493
    Rights issue.
    14 Dec 2023 Sally Evans Issued 9,557 $11,468
    Rights issue.
    14 Dec 2023 Sally Evans Issued 4,110 $4,932
    Rights issue.
    14 Dec 2023 Kathryn (Kate) McKenzie Issued 551 $661
    Rights issue.
    14 Dec 2023 Kathryn (Kate) McKenzie Issued 9,590 $11,508
    Rights issue.
    14 Dec 2023 Gordon Davis Issued 15,277 $18,332
    Rights issue.
    14 Dec 2023 Gordon Davis Issued 11,018 $13,221
    Rights issue.
    14 Dec 2023 John Mattick Issued 7,546 $9,055
    Rights issue.
    14 Dec 2023 John Mattick Issued 4,136 $4,963
    Rights issue.
    13 Dec 2023 Sally Evans Issued 32,900 $50,000
    Issue of securities. 32,900 NED Share Rights, vwap
    13 Dec 2023 Charlie Taylor Issued 32,900 $50,000
    Issue of securities. VWAP, 32,900 NED Share Rights
    04 Dec 2023 Kathryn (Kate) McKenzie Buy 53,000 $80,560
    On-market trade.
    01 Dec 2023 Michael Stanford Buy 32,468 $49,838
    On-market trade.
    11 Sep 2023 Jennifer (Jenny) Macdonald Buy 8,000 $20,229
    On-market trade.
    04 Sep 2023 Sally Evans Exercise 6,038 $20,000
    Conversion of securities. cash equivalent using the volume weighted average price
    04 Sep 2023 Sally Evans Buy 6,038 $20,000
    Conversion of securities. cash equivalent using the volume weighted average price
    04 Sep 2023 John Mattick Exercise 7,547 $25,000
    Conversion of securities. cash equivalent using the volume weighted average
    price
    04 Sep 2023 John Mattick Buy 7,547 $25,000
    Conversion of securities. cash equivalent using the volume weighted average
    price
    04 Sep 2023 Gordon Davis Buy 12,075 $40,000
    Conversion of securities. cash equivalent using the volume weighted
    average price
    04 Sep 2023 Gordon Davis Exercise 12,075 $40,000
    Conversion of securities. cash equivalent using the volume weighted
    average price
    01 Sep 2023 Kathryn (Kate) McKenzie Buy 20,000 $55,200
    On-market trade.
    31 Aug 2023 Jennifer (Jenny) Macdonald Buy 22,500 $61,200
    On-market trade.
    31 Aug 2023 Maxine Jaquet Issued 41,066 $114,984
    Conversion of securities.
    31 Aug 2023 Maxine Jaquet Exercise 41,066 $114,984
    Conversion of securities. 371,859 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Michael Philip Stanford Non-Executive Director Sep 2023
    Dr Stanford AM is a Non-Executive Director across a range of industries including healthcare, aged care and education. His experience includes ASX-listed businesses, private equity backed companies and not for profit organisations, and includes dealing with Federal and State Governments Commencing his career as a Doctor, Michael progressed into hospital administration and brings over 20 years experience as a Chief Executive Officer and Managing Director of large multi-campus and multi service health care organisations with national and international areas of operation, including St John of God Health Care, Australian Hospital Care Ltd, North-Western Health. North-Eastern Health Care Network and Austin & Repatriation Medical Centre. Dr Stanford is a former Non-Executive Director of Healthscope, Virtus Health and Australian Clinical Labs. He is currently the Chair of Diabetes Australia and genU, a disability support service provider. He is also a board member for the Royal Australian College of General Practitioners.
    Professor John Mattick Non-Executive Director Mar 2022
    Professor Mattick is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. From 2018 to 2010, he was Chief Executive of Genomics England, which was established by the UK government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established throughput NATA accredited DNA sequencing and genome analysis facilities. John was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council from 1997 to 2003, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He is a member of the Risk Management Committee.
    Mr Gordon Richard Davis Non-Executive Director Aug 2015
    Mr Davis has been an executive or non-executive director of ASX listed companies for 17 years. Before becoming a Non-Executive Director, he was Managing Director of AWB Limited between 2006 and 2010 and had a career, managing operating businesses in chemicals and agriculture. Gordon joined the Healius Board at a time of some corporate uncertainty, and has experience in governance and business transformation. He served as Policy Advisor to the federal Leader of the Opposition from 1990 to 1993 in the fields of environment, science and resources.
    Mr Paul Anderson Chief Executive OfficerManaging Director Mar 2024
    Mr Anderson had previously been Chief Executive Officer -Network Ten and Executive Vice President,ViacomCBS Networks Australia & NZ from 2015 to 2020, and was CFO and COO of Network Ten prior to that.
    Ms Kathryn (Kate) Mary McKenzie Non-Executive Director Feb 2021
    Ms McKenzie has experience in change management and digital transformation. She started her career in the public sector, where among other things, she was involved in aspects of health policy, including a state-based review of health system and re-negotiation of a Medicare agreement, and had involvement in working with Treasury on health budget allocations and methodologies. Kate joined Telstra in 2004 and held a range of executive roles in strategy, marketing, products and operations (responsible for networks, IT, field services and property). She was CEO of Chorus, a publicly listed NZ telco, for three years from 2017.She was appointed Chair of the Risk Management Committee in January 2023 and is a member of the People & Governance Committee.
    Ms Sally Evans Non-Executive Director Aug 2018
    Ms Evans has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. With leadership experience, Sally moved to asset management in social infrastructure covering debt and equity raisings, investor relations, acquisitions and governance. She is Chair of the People & Governance Committee and a member of the Risk Management Committee.
    Mr Charlie Taylor Non-Executive Director Mar 2023
    Mr Taylor has over 30 years of experience in advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australia's private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. Charlie initiated multi-year research efforts on healthcare, COVID response, productivity and innovation and has published articles and reports on healthcare reform lessons from around the globe. Charlie is currently a part-time senior board advisor at McKinsey for the Health and Public Sector practice, a Director of MacLauglin River Pastoral Company, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. Charlie is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. is a member of the People & Governance Committees.
    Mr Ravi Jeyaraj Non-Executive Director Nov 2023
    --
    Mrs Mary Weaver Company Secretary Mar 2023
    -
    Mr Stephen Humphries Company Secretary Mar 2023
    -
    Paul Anderson Chief Financial Officer
    -
    Mary Weaver Company Secretary
    -
    Stephen Humphries Company Secretary
    -
    Jan van Rooyen Group Executive
    -
    Janet Payne Group Executive Corporate Affairs
    -
    Mark Neeham Group Executive Government Affairs
    -
    John McKechnie Group Executive Pathology
    -
    Jon Eide Group Executive Commercial and Customer
    -
    Phil Lucas Group Executive Lumus Imaging
    -
    Arjun Narang Group Executive Operations Transformation
    -
    Prasad Arav Group Executive. Digital and Technology
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(i) 179,525,030 31.51%
    Citicorp Nominees Pty Limited 113,011,084 19.84%
    J P Morgan Nominees Australia Pty Limited 101,426,357 17.80%
    National Nominees Limited 41,431,994 7.27%
    Argo Investments Limited 19,132,634 3.36%
    Bnp Paribas Noms Pty Ltd <Drp> 13,878,419 2.44%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/ 3,770,723 0.66%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 3,577,160 0.63%
    Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 3,367,888 0.59%
    Ubs Nominees Pty Ltd 3,150,206 0.55%
    Rinrim Pty Ltd 2,362,047 0.41%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,204,931 0.21%
    Ecapital Nominees Pty Limited <Accumulation A/C> 1,032,081 0.18%
    Alphagen Capital Pty Ltd 1,000,000 0.18%
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(ii) 704,441 0.12%
    Joromada Pty Ltd 680,000 0.12%
    Netwealth Investments Limited <Wrap Services A/C> 636,689 0.11%
    Mr Gregory Anthony Thomas Bateman 636,213 0.11%
    Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 580,893 0.10%
    HSBC Custody Nominees (Australia) Limited Gsco Eca 569,088 0.10%

    Profile

    since

    Note